Remimazolam: First Approval
The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
Remimazolam (Anerem ® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation. Remimazolam was approved on 23 January 2020 in Japan for use in general anesthesia in adult patients. Remimazolam is also undergoing regulatory assessment in South Korea for this indication and for use in procedural sedation in the USA, the EU and China. This article summarises the major milestones in the development of remimazolam for this first approval for the induction and maintenance of general anaesthesia, and its potential upcoming approvals in general anaesthesia and procedural sedation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Kilpatrick (2007) · doi:10.1097/01.anes.0000267503.85085.c0 · Cited by 381
Antonik, L. J., Goldwater, D. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31823f0c28 · Cited by 374
Schüttler, J., Eisenried, A., Lerch, M., Fechner, J., Jeleazcov, C., & Ihmsen, H. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003103 · Cited by 338
Pastis, N. J., Yarmus, L. B., Schippers, F., Ostroff, R., Chen, A., Akulian, J., Wahidi, M., Shojaee, S., Tanner, N. T., Callahan, S. P., et al. (2019) · Chest · doi:10.1016/j.chest.2018.09.015 · Cited by 307
Rex, D. K., Bhandari, R., Desta, T., DeMicco, M. P., Schaeffer, C., Etzkorn, K., Barish, C. F., Pruitt, R., Cash, B. D., Quirk, D., et al. (2018) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2018.04.2351 · Cited by 302
Borkett, K. M., Riff, D. S., Schwartz, H. I., Winkle, P. J., Pambianco, D. J., Lees, J. P., & Wilhelm-Ogunbiyi, K. (2015) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000548 · Cited by 232
Remimazolam: Pharmacologic Considerations and Clinical Role in Anesthesiology
Wesolowski, A. M., Zaccagnino, M. P., Malapero, R. J., Kaye, A. D., & Urman, R. D. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1806 · Cited by 222
Wiltshire, H. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318241f68a · Cited by 215 · cited 2×
“Simulations based on population pharmacodynamic models showed that maximal sedation is reached within 3 min of IV remimazolam single-dose administration [33].”
BackgroundWorthington, M. T., Antonik, L. J., Goldwater, D. R., Lees, J. P., Wilhelm-Ogunbiyi, K., Borkett, K. M., & Mitchell, M. C. (2013) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3182a705ae · Cited by 184
Pambianco, D. J., Borkett, K. M., Riff, D. S., Winkle, P. J., Schwartz, H. I., Melson, T. I., & Wilhelm-Ogunbiyi, K. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2015.08.062 · Cited by 177
Research works printed but not linked: 2
- Acacia Pharma Group plc. Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO™ [media release]. 12 Mar 2020. https://www.acaciapharma.com/.
- PAION AG. PAION announces submission of the marketing authorization application for remimazolam in procedural sedation to the European Medicines Agency [media release]. 20 Nov 2019. https://www.paion.com/.
Cited by
Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent
Kilpatrick, G. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690875 · Cited by 262
“The steady-state volume of distribution was 88.1 L, terminal half-life 0.75 h, and mean residence time 0.51 h. Phase I single ascending dose trials of remimazolam besylate (Doi, 2014; Sheng et al., 2020) and remimazolam tosylate (Chen et al., 2020b) in Japanese and Chinese subjects report a similar profile to the init…”
BackgroundInfluentialRemimazolam: An Updated Review of a New Sedative and Anaesthetic
Hu, Q., Liu, X., Wen, C., Li, D., & Lei, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s384155 · Cited by 211
Zhang, X., Li, S., & Liu, J. (2021) · BMC Anesthesiology · doi:10.1186/s12871-021-01373-y · Cited by 165
Liu, T., Lai, T., Chen, J., Lu, Y., He, F., Chen, Y., & Xie, Y. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.851 · Cited by 146
“The exclusion criteria were as follows: (1) Severe cardiac dysfunction, ASA grade IV or above; (2) Allergic or contraindicated to benzodiazepines, opioids, propofol or their components; (3) Hypertension of grade 3 or above; (4) Dysfunction of the liver or kidney; and (5) Participation in another study within 4 weeks b…”
BackgroundShi, M., Chen, J., Liu, T., Dai, W., Zhou, Z., Chen, L., & Xie, Y. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s344240 · Cited by 133
Metadata
- Authors
- Keam, S. J.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Keam, Susan J.
- ORCID
- Keam, Susan J.
- Venue
- Drugs
- Published
- 2020-04
- Volume
- 80
- Issue
- 6
- Pages
- 625-633
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3015486573
- Cited by
- 188
- References
- 19
- Citations by year
- 2026: 26 · 2025: 39 · 2024: 46 · 2023: 29 · 2022: 29 · 2021: 18 · 2020: 1
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Veterinary › Small Animals › Veterinary Pharmacology and Anesthesia
- Keywords
- remimazolam, general anesthesia, procedural sedation, drug approval, regulatory evaluation, drug development milestones
- MeSH terms
- Anesthesia, General, Animals, Benzodiazepines, Colonoscopy, Humans, Hypnotics and Sedatives, Molecular Conformation, Drug Approval, Anesthetics, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remimazolam: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01299-8
- The paper
- Keam, S. J. (2020). Remimazolam: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01299-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.